Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
Globe Newswire•27/10/2026•07:00 ET
0
Key Highlights
- ➤Arvinas will report third quarter 2026 financial results November 3, 2026
- ➤Management will provide a corporate update during an 8:00 a.m. ET webcast
- ➤Arvinas and Pfizer developed the first FDA-approved PROTAC
- ➤Arvinas is advancing investigational drugs across oncology and neurodegenerative disorders
NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, November 3, 2026 at 8:00 a.m. ET.
The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.
Get started
Create a free account to read the full story.